Onco-Targets – Making loss of SFRP tumour suppressor function druggable
The invention discloses molecules, which are activated,
when function of Secreted Fizzled Related Protein 1 (SFRP1) is lost. SFRP1 is known to have tumour suppressor function and its loss is associated to tumour progression and poor survival. Access to the signalling pathways regulated by SFRP1 leads to novel targets for cancer therapy and diagnosis. Such druggable targets open the route to screening of small molecules and design of monoclonal antibodies, thereby enabling the development of innovative oncological treatments as well as new diagnostic markers.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Machine learning algorithm reveals long-theorized glass phase in crystal
Scientists have found evidence of an elusive, glassy phase of matter that emerges when a crystal’s perfect internal pattern is disrupted. X-ray technology and machine learning converge to shed light…
Mapping plant functional diversity from space
HKU ecologists revolutionize ecosystem monitoring with novel field-satellite integration. An international team of researchers, led by Professor Jin WU from the School of Biological Sciences at The University of Hong…
Inverters with constant full load capability
…enable an increase in the performance of electric drives. Overheating components significantly limit the performance of drivetrains in electric vehicles. Inverters in particular are subject to a high thermal load,…